Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,406
datasets available to search
ShareScore release 0.9.0
Dataset results
1,406 results for “Migraine”
Subjective sleep quality and sleep architecture in patients with migraine: a meta-analysis
<p>Objectives: Sleep disturbance is often associated with migraine. However, there is a paucity of research investigating objective and subjective measures of sleep in migraine patients. This meta-analysis aims to determine whether there are differences in subjective sleep quality measured using the Pittsburgh Sleep Quality Index (PSQI), and objective sleep physiology measured using polysomnography between adult and pediatric patients, and healthy controls.</p> <p>Methods: This review was pre-registered on PROSPERO (CRD42020209325). A systematic search of five databases (Embase, MEDLINE®, Global Health, APA PsycINFO, APA PsycArticles, last searched: 12/17/2020) was conducted to find case-controlled studies which measured polysomnography and/or PSQI in patients with migraine. Pregnant participants and those with other headache disorders were excluded. Effect sizes (Hedges' <i>g</i>) were entered into a random effects model meta-analysis. Study quality was evaluated with the Newcastle Ottawa Scale, and publication bias with Egger's regression test.</p> <p>Results: 32 studies were eligible, of which 21 measured PSQI and/MIDAS in adults, 6 measured PSG in adults and 5 in children. The overall mean study quality score was 5/9, and this did not moderate any of the results, and there was no risk of publication bias. Overall, adults with migraine had higher PSQI scores than healthy controls (<i>g</i>=0.75, <i>p</i> < .001, 95% confidence interval [95%CI]: 0.54 - 0.96). This effect was larger in those with chronic rather than episodic condition (<i>g</i>=1.03, <i>p </i>< .001, 95%CI: 0.37 - 1.01, <i>g </i>= 0.63, <i>p </i>< .001, 95%CI: 0.38 - 0.88 respectively). For polysomnographic studies, adults and children with migraine displayed a lower percentage of REM sleep (<i>g</i>=-0.22, <i>p</i> = 0.017, 95%CI: -0.41 - -0.04, <i>g</i> = -0.71, <i>p</i> = 0.025, 95%CI: -1.34 - -0.10 respectively) than controls. Pediatric patients displayed less total sleep time (<i>g</i>=-1.37, <i>p </i>= 0.039, 95%CI: -2.66 - -0.10), more wake (<i>g</i>=0.52, <i>p </i>< .001, 95%CI: 0.08 – 0.79) and shorter sleep onset latency (<i>g</i>=-0.37, <i>p </i>< .001, 95%CI: -0.54 - -0.21) than controls.</p> <p>Discussion: People with migraine have significantly poorer subjective sleep quality and altered sleep physiology compared to healthy individuals. Further longitudinal empirical studies are required to enhance our understanding of this relationship.</p>
Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine
ClinicalTrials.gov study NCT03855137. IPD Sharing: YES. Countries: 17. Publications: 10.
Mindfulness and Mechanisms of Pain Processing in Adults With Migraines
ClinicalTrials.gov study NCT02695498. IPD Sharing: YES. Countries: 1. Publications: 2.
A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age
ClinicalTrials.gov study NCT04458857. IPD Sharing: YES. Countries: 9. Publications: 1.
Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients
ClinicalTrials.gov study NCT03927144. IPD Sharing: NO. Countries: 18. Publications: 1.
A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies
ClinicalTrials.gov study NCT03096834. IPD Sharing: YES. Countries: 16. Publications: 6.
Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients
ClinicalTrials.gov study NCT03867201. IPD Sharing: YES. Countries: 9. Publications: 1.
Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine Patients
ClinicalTrials.gov study NCT03333109. IPD Sharing: YES. Countries: 11. Publications: 3.
Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants
ClinicalTrials.gov study NCT04492020. IPD Sharing: YES. Countries: 1. Publications: 4.
A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder
ClinicalTrials.gov study NCT04041284. IPD Sharing: YES. Countries: 13. Publications: 1.
Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine
ClinicalTrials.gov study NCT03939312. IPD Sharing: YES. Countries: 1. Publications: 4.
Treatment for Migraine and Mood (Team-M)
ClinicalTrials.gov study NCT04992494. IPD Sharing: YES. Countries: 1. Publications: 0.
Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study
ClinicalTrials.gov study NCT04084314. IPD Sharing: YES. Countries: 1. Publications: 1.
Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine
ClinicalTrials.gov study NCT03828539. IPD Sharing: YES. Countries: 1. Publications: 2.
Subjective sleep quality and sleep architecture in patients with migraine: a meta-analysis
Open the record for dataset details and reuse information.
A SLC1A3 variant associated with hemiplegic migraine and acetazolamide-responsive MRS changes
<p>Familial hemiplegic migraine (FHM) is a group of rare familial disorders caused, in most cases, by mutations in <em>CACNA1A</em> and <em>ATP1A2</em>.<sup><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357413/#R1">1</a></sup> Heterozygous mutations in solute carrier family 1 member 3 (<em>SLC1A3</em>), encoding glial glutamate transporter, are associated with episodic ataxia type 6 (EA6).<sup><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357413/#R2">2</a>,<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357413/#R3">–</a><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357413/#R5">5</a></sup> In addition to episodic ataxia (EA), alternating hemiplegia and hemiplegic migraine have been reported twice in patients with EA6.<sup><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357413/#R2">2</a>,<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357413/#R4">4</a></sup> Mutations in <em>SLC1A3</em> are very rare; screenings in cohorts of EA and alternating hemiplegia have yielded either negative results<sup><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357413/#R3">3</a>,<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357413/#R6">6</a>,<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357413/#R7">–</a><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357413/#R8">8</a></sup> or variants of unclear significance.<sup>e-1--e-3</sup> Herein, we characterize a patient featuring sporadic hemiplegic migraine (SHM) responsive to acetazolamide (ACZ) and mild cerebellar atrophy associated with a new variant in <em>SLC1A3.</em> We also report the utility of proton magnetic resonance spectroscopy (MRS) for this condition.</p>
Dual FAAH/MAGL inhibition in migraine pain
<p>This dataset comprises the findings obtained in the study aimed at investigating the effect of dual inhibition of anandamide and 2 arachidonyl glycerol (2-AG) catabolic pathways (FAAH and MAGL respectively) in the nitroglycerin (NTG)-based animal model of migraine. The dual inhibitor JZL195 was administered to male rats 2h after NTG or vehicle injection. Rats were then exposed to the open field and the orofacial formalin tests 4 hours after NTG or vehicle. At the end of the evaluations, they were sacrificed to evaluate calcitonin gene-related peptide (CGRP) serum levels and gene expression of CGRP and pro-inflammatory cytokines in the cervical spinal cord and the trigeminal ganglion.</p> <p>We also investigated the effect of subtype-selective antagonist for cannabinoid receptors 1 and 2 (AM251 and AM630, respectively) on the behavioral JZL195 effects. The dual inhibitor significantly reduces the NTG-induced trigeminal hyperalgesia and pain-associated behavior, possibly via cannabinoid 1 receptors-mediated action, but it did not change the hypomotility and the anxiety behaviors induced by NTG. The decreased hyperalgesia was associated with a reduction in CGRP and cytokine gene expression levels in central and peripheral structures and reduced CGRP serum levels. These data suggest an antinociceptive synergy of the endocannabinoid action in peripheral and central sites, confirming that this system participates in reduction of cephalic pain signals.</p> <p> </p> <p>The <em>in vivo</em> and <em>ex vivo</em> assessments were:</p> <ol> <li>Distance (expressed in meters) travelled in the apparatus, time spent (expressed in seconds) in the center of the apparatus, number of rearing, time spent in grooming behavior (expressed in seconds) were evaluated in the open field test. Each animal was placed in a 92 x 92 cm arena and video recorded for 10 minutes. The analysis was done manually (for rearing and grooming) and with the ANY-Maze software (for total distance and time in the centre).</li> <li>Pain-related behavior in the orofacial formalin test: the face rubbing was measured counting the seconds the animal spent grooming the injected area (upper lip, lateral to the nose) with the ipsilateral forepaw or hindpaw 0–6 min (Phase I) or 12–45 min (Phase II) after formalin injection (50 µl, s.c.). The observation time was divided into 15 blocks of 3 min each.</li> <li>mRNA expression levels: calcitonin gene-related peptide (CGRP), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) mRNA were evaluated in cervical spinal cord and trigeminal ganglia. mRNA levels were measured by rt-PCR. All samples were assayed in triplicate and gene expression levels were calculated according to 2−∆∆Ct = 2− (∆Ct gene − ∆Ct housekeeping gene) formula by using Ct (cycle threshold) values.</li> <li>CGRP protein levels in serum: the blood samples were collected in clot activator with gel separator serum tubes and centrifugated for 15 min at 1000×g at 2-8° C. Serum CGRP levels were measured using a commercial enzyme-linked immuno-sorbent assay (ELISA) kit (Elabsciences). Data are expressed as pg/ml.</li> </ol> <p>Results: The dual inhibitor significantly reduced the NTG-induced trigeminal hyperalgesia and pain-associated behavior, possibly via cannabinoid 1 receptors-mediated action, but it did not change the hypomotility and the anxiety behaviors induced by NTG. The decreased hyperalgesia was associated with a reduction in CGRP and cytokine gene expression levels in central and peripheral structures and reduced CGRP serum levels.</p>
Characterization of the peripheral FAAH inhibitor, URB937, in animal models of acute and chronic migraine
<p>This dataset comprises the findings obtained in the study aimed at investigating the effects of URB937, a peripherally restricted fatty-acid amide hydrolase (FAAH) inhibitor, in two rat models that capture aspects of acute and chronic migraine, and are based on single or repeated administration of the vasodilating drug, nitroglycerin (NTG). The orofacial nocifensive behavior and mRNA levels of neuropeptides and pro-inflammatory cytokines along with tissue levels of anandamide and palmitoylethanolamide (PEA) were measured in trigeminal ganglia and medulla.</p> <p>All evaluations were made in rats that received a single injection of URB937 (1 mg/kg i.p.) either before or after NTG administration (10 mg/kg, i.p.) within the acute model, or daily URB937 (1 mg/kg i.p.) injections within the NTG (5 mg/kg, i.p.) chronic model. In the acute migraine model, we also investigated the effect of subtype-selective antagonist for cannabinoid receptors 1 and 2 (AM251 and AM630, respectively). Specifically, we achieved the following evaluations:</p> <p>1. Measurement of AEA and PEA levels: medulla and trigeminal ganglia were homogenized in cold methanol (2 ml) containing AEA-d4 and PEA-d4 as internal standards. After extraction the lipids were measured using a Xevo TQ UPLC-MS/MS system equipped with a reversed-phase BEH C18 column (2.1 × 50 mm, 1.7 μm particle size) (Waters, Milford, USA).</p> <p>2. Pain-related behavior in the orofacial formalin test: the face rubbing was measured counting the seconds the animal spent grooming the injected area (upper lip, lateral to the nose) with the ipsilateral forepaw or hindpaw 0–6 min (Phase I) or 12–45 min (Phase II) after formalin injection (50 µl, s.c.). The observation time was divided into 15 blocks of 3 min each.</p> <p>3. mRNA expression levels: calcitonin gene-related peptide (CGRP), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha) mRNA were evaluated in in medulla and trigeminal ganglia. mRNA levels were measured by rt-PCR. All samples were assayed in triplicate and gene expression levels were calculated according to 2−∆∆Ct = 2− (∆Ct gene − ∆Ct housekeeping gene) formula by using Ct (cycle threshold) values.</p>
Migraine monoclonal antibodies against CGRP change brain activity depending on ligand or receptor target – an fMRI study
<p>Background: Monoclonal antibodies (mAbs) against calcitonin gene-related peptides (CGRP) are novel treatments for migraine prevention. Based on a previous functional imaging study which investigated the CGRP receptor mAb (erenumab), we hypothesized that (i) the CGRP ligand mAb galcanezumab would alter central trigeminal pain processing; (ii) responders to galcanezumab treatment would show specific hypothalamic modulation in contrast to non-responders; and (iii) the ligand and the receptor antibody differ in brain responses.</p> <p>Methods: Using an established trigeminal nociceptive functional magnetic imaging paradigm, 26 migraine patients were subsequently scanned twice: before and 2–3 weeks after administration of galcanezumab.</p> <p>Results: We found that galcanezumab decreases hypothalamic activation in all patients and that the reduction was stronger in responders than in non-responders. Contrasting erenumab and galcanezumab showed that both antibodies activate a distinct network. We also found that pre-treatment activity of the spinal trigeminal nucleus (STN) and coupling between the STN and the hypothalamus covariates with the response to galcanezumab.</p> <p>Conclusions: These data suggest that despite relative impermeability of the blood-brain barrier for CGRP mAb, mAb treatment induces certain and highly specific brain effects which may be part of the mechanism of their efficacy in migraine treatment.</p> <p>Funding: This work was supported by the German Ministry of Education and Research (BMBF) of ERA-Net Neuron under the project code BIOMIGA (01EW2002 to AM) and by the German Research Foundation (SFB936-178316478-A5 to AM). The funding sources did not influence study conduction in any way. </p> <p>Clinical trial number: The basic science study was preregistered in the Open Science Framework (https://osf.io/m2rc6).</p>
Modelling migraine-related features in the nitroglycerin animal model: trigeminal hyperalgesia is associated with affective status and motor behaviour
<p>This dataset comprises the findings obtained in the study aimed at exploring the correlation between trigeminal hyperalgesia and affective status or behavioral components in a migraine-specific animal model based on nitroglycerin administration (see article <em>Modelling migraine-related features in the nitroglycerin animal model: trigeminal hyperalgesia is associated with affective status and motor behaviour).</em></p> <p>In vivo assessments performed in male Sprague-Dawley rats four hours after treatment with nitroglycerin (10mg/kg, i.p.) or its vehicle:</p> <p>- in the open field test were evaluated: time spent (expressed in seconds) in the center of the apparatus as a measure of anxiety; distance (expressed in meters) travelled in the apparatus as a measure of motor behaviour; number of rearings as a measure of exploratory behaviour; time spent in grooming behavior (expressed in seconds) used as nociception index;</p> <p>- evaluation of trigeminal hyperalgesia in the orofacial formalin test: the face rubbing was measured counting the seconds the animal spent grooming the injected area (upper lip, lateral to the nose) with the ipsilateral forepaw or hindpaw 0–3 min (Phase I) or 12–45 min (Phase II) after formalin injection (50 µl, s.c.). The observation time was divided into 15 blocks of 3 min each.</p> <p><strong>RESULTS</strong></p> <p>The data analysis shows an inverse correlation between trigeminal hyperalgesia and motor or exploratory behavior, and a positive association with anxiety-like behavior of spontaneous grooming.</p> <p>These findings further expand on the translational value of the migraine-specific model based on nitroglycerin administration and prompt additional parameters that can be investigated to explore the complexity of the disease.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.